Insulin is one of the most-used medicines across the world for treating Type 2 diabetes. A recently-published study, however, suggests that things would not be the same after a few years. According to this study, usage rates of Insulin are expected to rise exponentially by 2030 while the demand will also be increased. This will create a situation where many patients don’t have access to this medicine. The study was conducted by a group of researchers in Stanford University and the study has more statistics to show about how worse the conditions would turn into.
It is expected that 511 million people will be suffering from Type 2 diabetes by 2030, and the current stats are standing at 406 Million. Out of the extra people who are expected to acquire the situation, citizens of the US, China and India will be contributing the most. The research was based on the data from International Diabetes Federation, along with 14 other studies that were done on the matter. Altogether, the researchers were able to analyze the data of more than 60% of people across the world who have diabetes. The study is also showing the signs why insulin consumption would increase in the long run.
In many regions, including Africa, governments are trying to make insulin affordable for the commons in the country. This too will increase the overall consumption rates of the drug, contributing to the global trend in the long run. It is expected that more people would not be able to live without the sufficient amount of the drug. However, the real problem is the increasing price of the drug, which has been inaccessible for most of the population as well. Therefore, the team also recommends that we should analyze other methods that can reduce the dependence of insulin.
Over 4 years’ experience in the research industry. Experience with research and consulting projects, catering to domains such as ICT, Health & Pharma, and packaging. Managed projects on both B2B as well as B2C perspective, which includes consumer preference analysis, interviews with key executives, etc.